This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.

开始日期2022-11-30

申办/合作机构

National Cancer Institute

NCT05151328

/ Completed临床3期

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Plecanatide in the Treatment of Functional Constipation in Chinese Patients for up to 12 Weeks

This is a multi-center, randomized, double-blind, Placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Plecanatide in the treatment of Functional Constipation in Chinese patients for up to 12 weeks.
Patients will enter a Screening period which must undergo a 2-week Pre-Treatment assessment, they will complete daily assessments of electronic dairy to demonstrate the eligibility.
Eligible subjects will be randomized into Plecanatide 3 mg group or Placebo group at Visit 1 at the ratio of 1:1 and take an oral dose of study treatment continuously for 12 weeks. For 2 weeks after complete dosing patients will continue to complete daily electronic dairy. Patients will then return to the clinical site for efficacy and safety assessment as part of an End of Study visit. The planned duration of participation in this study will be 154 days and up to 164 days with all windows considered.

开始日期2022-03-18

申办/合作机构

山东罗欣药业集团股份有限公司

CTRI/2022/03/040704

/ Completed临床3期

A Randomized, Double-Blind, Multicentric, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Plecanatide in Subjects with Chronic Idiopathic Constipation or Irritable Bowel Syndrome with Constipation.

开始日期2022-03-05

申办/合作机构

MSN Laboratories Pvt Ltd.

100 项与普卡那肽相关的临床结果

登录后查看更多信息

100 项与普卡那肽相关的转化医学

登录后查看更多信息

100 项与普卡那肽相关的专利（医药）

登录后查看更多信息

项与普卡那肽相关的文献（医药）

2024-10-01·Journal of Managed Care & Specialty Pharmacy

A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States

Article

作者: Terasawa, Emi ; Terreri, Brian ; Du, Shawn ; Lu, Mei ; Moshiree, Baharak ; Boules, Mena ; Feuerstadt, Paul ; Cash, Brooks D. ; Ayyagari, Rajeev ; Nguyen, Linda ; Westermeyer, Ben ; Lembo, Anthony ; Pi, Selina

BACKGROUNDAt present, 4 prescription therapies have been approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation (CIC) in adults.OBJECTIVESTo compare persistence with and adherence to prucalopride vs 3 other prescription medications for CIC in a US population.METHODSThis retrospective, observational cohort study used data from the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (January 2015-June 2020). Inclusion criteria were patients (aged ≥18 years) with at least 1 prescription fill for prucalopride, lubiprostone, linaclotide, or plecanatide on or after April 2, 2019 (commercial availability of prucalopride), and at least 1 constipation-related diagnosis code. Persistence was assessed by time to discontinuation, and adherence was assessed by the proportion of days covered (PDC) and the proportion of patients who achieved PDC of at least 80%. Adjusted hazard ratios (HRs) for discontinuation and odds ratios for adherence were calculated.RESULTSA total of 14,700 patients (mean age = 48.3 years; female = 81.9%) were included (prucalopride, n = 675; lubiprostone, n = 1,591; linaclotide, n = 11,105; plecanatide, n = 1,329). After adjusting for confounding factors, the HRs for discontinuation were significantly higher for all comparator medications compared with prucalopride after 2 months (HR [95% CI]: lubiprostone, 1.70 [1.48-1.95]; linaclotide, 1.25 [1.10-1.41]; plecanatide, 1.31 [1.13-1.51], all P < 0.001). The unadjusted mean (SD) PDC was 0.53 (0.32) with prucalopride compared with 0.41 (0.31); P less than 0.001 with lubiprostone, 0.48 (0.31), P less than 0.05 with linaclotide, and 0.48 (0.29), P = 0.98 with plecanatide. The comparator medications were all associated with lower odds of achieving PDC of at least 80% relative to prucalopride (odds ratio [95% CI]: lubiprostone, 0.52 [0.40-0.69], P < 0.001; linaclotide, 0.73 [0.58-0.93], P = 0.009; plecanatide, 0.70 [0.53-0.93], P = 0.015).CONCLUSIONSThe findings of this study indicate that prucalopride has higher treatment persistence and adherence compared with other CIC prescription medications. This research represents the first instance of a real-world claims study showcasing such outcomes.

2024-06-01·Heliyon

Greater cane rat algorithm (GCRA): A nature-inspired metaheuristic for optimization problems

Article

作者: Mirjalili, Seyedali ; Pal, Jayanta ; Abualigah, Laith ; Ezugwu, Absalom E ; Agushaka, Jeffrey O ; Saha, Apu K

This paper introduces a new metaheuristic technique known as the Greater Cane Rat Algorithm (GCRA) for addressing optimization problems. The optimization process of GCRA is inspired by the intelligent foraging behaviors of greater cane rats during and off mating season. Being highly nocturnal, they are intelligible enough to leave trails as they forage through reeds and grass. Such trails would subsequently lead to food and water sources and shelter. The exploration phase is achieved when they leave the different shelters scattered around their territory to forage and leave trails. It is presumed that the alpha male maintains knowledge about these routes, and as a result, other rats modify their location according to this information. Also, the males are aware of the breeding season and separate themselves from the group. The assumption is that once the group is separated during this season, the foraging activities are concentrated within areas of abundant food sources, which aids the exploitation. Hence, the smart foraging paths and behaviors during the mating season are mathematically represented to realize the design of the GCR algorithm and carry out the optimization tasks. The performance of GCRA is tested using twenty-two classical benchmark functions, ten CEC 2020 complex functions, and the CEC 2011 real-world continuous benchmark problems. To further test the performance of the proposed algorithm, six classic problems in the engineering domain were used. Furthermore, a thorough analysis of computational and convergence results is presented to shed light on the efficacy and stability levels of GCRA. The statistical significance of the results is compared with ten state-of-the-art algorithms using Friedman's and Wilcoxon's signed rank tests. These findings show that GCRA produced optimal or nearly optimal solutions and evaded the trap of local minima, distinguishing it from the rival optimization algorithms employed to tackle similar problems. The GCRA optimizer source code is publicly available at: https://www.mathworks.com/matlabcentral/fileexchange/165241-greater-cane-rat-algorithm-gcra.

2024-06-01·Environmental Research

The power of attention: Government climate-risk attention and agricultural-land carbon emissions

Article

作者: Zhao, He ; Liu, Lina ; Chen, Minghao ; Xiao, Hongyu

Climate change is a common challenge faced by all humanity. Promoting emission and carbon reduction in agricultural land is the most important priority for addressing climate change and realizing sustainable development. Based on data from 296 prefecture-level cities in China from 2011 to 2021, this study utilizes machine-learning and text-analysis methods to construct an indicator of government climate-risk attention (GCRA). It combines a two-way fixed-effects model to investigate how GCRA affects agricultural-land carbon emissions (ALCE) and carbon intensity (ALCI) and the mechanism of the impact. The results indicate that (1) GCRA substantially reduces ALCE and ALCI, and the conclusions are robust to a battery of tests. Furthermore, (2) mechanism analysis reveals that GCRA primarily uses three mechanisms-strengthening environmental regulation, promoting agricultural green-technology innovation, and upgrading agricultural-land mechanization-to reduce ALCE and lower ALCI. Additionally, (3) heterogeneity analysis suggests that the carbon-emission reduction effect of GCRA is more significant in the east, in arid and humid climate zones, and in non-grain-producing regions. Finally, (4) spatial-spillover effect analysis and quantile regression results demonstrate that GCRA also significantly inhibits carbon emissions and the carbon intensity of nearby agricultural land, with the inhibition effect becoming more pronounced at higher levels of government attention. This study's discoveries are helpful in promoting the emission reduction and carbon sequestration of agricultural land and provide references for developing countries to cope with climate change.

项与普卡那肽相关的新闻（医药）

2024-08-01

·ir.bauschhealth.com

Bausch Health Announces Second Quarter 2024 Results

Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basis Consolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10% Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance LAVAL, QC, August 1, 2024 – Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter. "We continued our momentum in the second quarter, delivering our fifth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA, underscoring the strength of our product and geographic footprint and reinforcing our strategy. We remain focused on advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive growth globally. I'm proud of the hard work and accomplishments of our team, who work tirelessly to improve the health of patients worldwide," said Thomas J. Appio, Chief Executive Officer, Bausch Health. Second Quarter 2024 Revenue Performance Total consolidated reported revenues were $2.40 billion for the second quarter of 2024, compared with $2.17 billion in the second quarter of 2023, an increase of $236 million, or 11%. Excluding the impact of foreign exchange of $25 million, acquisitions of $104 million, and divestitures and discontinuations of $14 million, revenue increased by 8% organically1 compared with the second quarter of 2023. Reported revenues by segment were as follows: Three Months Ended June 30, Reported Change Change at Constant Currency1 (Non-GAAP) Change in Organic Revenue1 (Non-GAAP) (in millions) 2024 2023 Amount Pct. Total Bausch Health Revenues $2,403 $2,167 $236 11% 12% 8% Bausch Health (excl. B+L) $1,187 $1,132 $55 5% 5% 6% Salix segment $558 $557 $1 —% —% 1% International segment $276 $259 $17 7% 5% 6% Solta Medical segment $102 $88 $14 16% 19% 19% Diversified segment $251 $228 $23 10% 10% 12% Bausch + Lomb segment $1,216 $1,035 $181 17% 20% 10% Salix Segment Salix segment reported revenues were $558 million for the second quarter of 2024, compared with $557 million for the second quarter of 2023. Excluding the impact of divestitures and discontinuations of $5 million, segment revenues increased 1% on an organic1 basis. Xifaxan® revenues grew 10% compared with the second quarter of 2023, which was offset by declines in Relistor®, Trulance®, and certain non-promoted products. International Segment International segment reported revenues were $276 million for the second quarter of 2024, compared with $259 million for the second quarter of 2023, an increase of $17 million, or 7%. Excluding the impact of foreign exchange of $5 million and divestitures and discontinuations of $3 million, segment revenues increased organically1 by 6% compared with the second quarter of 2023, led by double-digit growth in Canada and solid growth in Latin America. Solta Medical Segment Solta Medical segment reported revenues were $102 million for the second quarter of 2024, compared with $88 million in the second quarter of 2023, an increase of $14 million, or 16%, which was driven by growth in Asia-Pacific, led by South Korea. Excluding the impact of foreign exchange of $3 million, segment revenues increased organically1 by 19% compared with the second quarter of 2023. Diversified Segment Diversified segment reported revenues were $251 million for the second quarter of 2024, compared with $228 million for the second quarter of 2023, an increase of $23 million, or 10%. Excluding the impact of divestitures and discontinuations of $4 million, segment revenues increased 12% on an organic1 basis, primarily attributable to increases in sales in Dermatology and Neurology. Bausch + Lomb Segment Bausch + Lomb segment reported revenues were $1,216 million for the second quarter of 2024, compared with $1,035 million for the second quarter of 2023, an increase of $181 million, or 17%. Excluding the impact of foreign exchange of $27 million, acquisitions of $104 million and divestitures and discontinuations of $2 million, the Bausch + Lomb segment revenues increased organically1 by 10% compared with the second quarter of 2023, driven by increases across all business units. 1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures and ratios to the most directly comparable GAAP measure. Read More View original release here: https://www.accesswire.com/viewarticle.aspx?id=894962

财报并购

2024-07-03

·罗欣药业

重磅！罗欣药业注射用LX22001获批开展临床试验

近日，罗欣药业（002793.SZ）下属子公司山东罗欣药业集团股份有限公司、罗欣药业（上海）有限公司收到国家药品监督管理局下发的注射用LX22001的《药物临床试验批准通知书》。注射用LX22001是罗欣药业创新药替戈拉生的注射剂型，是钾离子竞争性酸阻滞剂类药物（P-CAB），目前在全球范围内尚无产品上市。此次获准临床的注射用LX22001开发适应症为：（1）本品可作为当口服疗法不适用时，用于下列病症的替代疗法：反流性食管炎、十二指肠溃疡；（2）消化性溃疡出血。作为全新机制的P-CAB相比于传统质子泵抑制剂（PPI），具有更快速起效、更强效持久抑酸、服用更方便等特点，首剂即可达到更大抑酸效果，有效抑制夜间酸突破等优势[1][2]。目前，最新的中国消化领域疾病指南已将P-CAB口服剂型作为反流性食管炎的首选药物之一[3]。注射剂型的临床应用场景与口服剂型存在差异，更多应用于手术、住院等。随着P-CAB被越来越多的专家、患者认可，未来有望成为主流抑酸药物逐渐替代PPIs。近年来，罗欣药业加速创新转型，坚持“自主研发+合作研发”双轨并进，聚焦优势领域，逐步打造了以消化、呼吸系统疾病为主线、兼顾抗肿瘤等治疗领域的创新产品研发管线，多个创新产品为临床用药带来新选择。 2022年4月，公司首款1类新药替戈拉生片“反流性食管炎”适应症获批上市,已被纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2022年）》。 2023年11月，替戈拉生片新增“十二指肠溃疡”适应症获批上市。 2023年12月，替戈拉生片新适应症“与适当的抗菌疗法联用根除幽门螺杆菌”上市申请获得国家药品监督管理局受理，该适应症的临床数据根除率优效于对照组艾司奥美拉唑，为该适应症首个根除率超90%的P-CAB。 2024年5月，替戈拉生片新适应症“与适当的抗菌疗法联用根除幽门螺杆菌”III期临床研究入选2024年美国消化疾病周（DDW）口头报告[4]。 2024年1月，公司消化领域布局的另一款新药普卡那肽片的Ⅲ期临床试验已完成，达成主要疗效终点，有望成为国内首个治疗慢性特发性便秘的鸟苷酸环化酶激动剂。 2024年6月，罗欣药业与国际领先的AI+BT微生态研发企业深圳未知君就肠道菌群移植技术（FMT）在合作区域内合作范围的独家代理经销合作达成一致意见。深耕医药行业36年，罗欣药业将持续秉持“传递健康”理念，深入实施科技创新，关注未被满足的临床需求，持续推进高质量创新药品研发成果落地，为全球患者提供更多创新药物选择。参考文献： [1].Hunt RH, et al. Curr Treat Options Gastroenterol.2018 Dec;16(4):570-590. [2].Kim JS, Seo SI, Kang SH, Lee SK, Kim AR, Park HW, Kim BT, Song GS. Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial. J Neurogastroenterol Motil. 2023 Jan 30;29(1):58-64. [3]. 中华医学会消化病学分会.2020年中国胃食管反流病专家共识[J].中华消化杂志, 2020, 40(10):649-663. [4].Liya Zhou, Zhiqiang Song. A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PHASE III CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF BISMUTH QUADRUPLE THERAPY CONTAINING TEGOPRAZAN COMPARED TO ESOMEPRAZOLE IN ERADICATING HELICOBACTER PYLORI IN CHINA. Presentation Number: 6562. 内容来源于网络，如有侵权，请联系删除。

临床3期申请上市

2024-07-01

·E药经理人

罗欣药业：收到《药物临床试验批准通知书》P-CAB注射剂即将启动临床

近日，罗欣药业（002793.SZ）公告，其下属子公司山东罗欣药业集团股份有限公司、罗欣药业（上海）有限公司收到国家药品监督管理局下发的注射用LX22001的《药物临床试验批准通知书》。注射用LX22001即公司创新药替戈拉生的注射剂型，是钾离子竞争性酸阻滞剂类药物（P-CAB），目前在全球范围内尚无产品上市。罗欣药业表示，本次注射用LX22001临床试验获得批准，体现了公司在巩固核心领域优势的基础上持续发力，彰显了公司科技创新能力，有助于丰富产品管线，提升公司创新药优势领域核心竞争力。记者查阅相关资料了解到，作为全新机制的P-CAB相比于传统质子泵抑制剂（PPI），具有更快速起效、更强效持久抑酸、服用更方便等特点，首剂即可达到更大抑酸效果，有效抑制夜间酸突破等优势[1][2]。目前，最新的中国消化领域疾病指南已将P-CAB口服剂型作为反流性食管炎的首选药物之一[3]。此次获准临床的注射用LX22001开发适应症为：（1）本品可作为当口服疗法不适用时，用于下列病症的替代疗法：反流性食管炎、十二指肠溃疡；（2）消化性溃疡出血。注射剂型的临床应用场景与口服剂型存在差异，更多应用于手术、住院等。2023年中国抑酸市场 Value IQVIA数据显示注射剂+口服剂市场在经历国家集采、重点监控目录及医保PPI针剂加限等政策调控后仍有超200亿市场规模，其中注射剂占55%的市场份额。罗欣药业作为上一代PPI注射剂的销售王者，布局P-CAB注射剂型将有利于巩固其消化领域市场地位，为消化类产品业绩提升带来更大想象空间。随着P-CAB被越来越多的专家、患者认可，未来有望成为主流抑酸药物逐渐替代PPIs。近年来，罗欣药业持续深化创新转型聚焦医药工业提升消化领域核心优势，已取得多项突破。2022年4月，公司首款1类新药替戈拉生片“反流性食管炎”适应症获批上市。2023年11月，替戈拉生片新增“十二指肠溃疡”适应症获批上市。2023年12月，替戈拉生片新适应症“与适当的抗菌疗法联用根除幽门螺杆菌”上市申请获得国家药品监督管理局受理，该适应症的临床数据根除率优效于对照组艾司奥美拉唑，为该适应症首个根除率超90%的P-CAB，2024年5月，该适应症III期临床研究入选2024年美国消化疾病周（DDW）口头报告[4]。 2024年1月，公司消化领域布局的另一款新药普卡那肽片的Ⅲ期临床试验已完成，达成主要疗效终点，有望成为国内首个治疗慢性特发性便秘的鸟苷酸环化酶激动剂。中国受便秘困扰的成人达到9870万人~2.86亿人。随着生活节奏加快、饮食结构改变、人口老龄化及社会心理因素的影响，便秘患病率呈上升趋势。IQVIA数据显示同类促泌剂产品2023年美国销售金额超28亿美金。值得一提的是，罗欣药业还积极拓展消化领域产品布局，今年达成合作的创新医疗技术有望为公司贡献新的业绩增量。2024年6月，罗欣药业与国际领先的AI+BT微生态研发企业深圳未知君就肠道菌群移植技术（FMT）在合作区域内合作范围的独家代理经销合作达成一致意见。根据协议约定公司采购该项目业绩指标第一年为1500万元，第三年为5000万元，第五年即达到2亿元，复合增长率91.09%。作为一种新兴的治疗方法，FMT受到了国内外的广泛关注。越来越多的证据表明FMT可用于治疗多种菌群失调相关性疾病，且应用安全、范围广泛、潜力巨大。国际登记在册的FMT临床试验达489个，在治疗艰难梭菌感染（CDI）方面FMT已表现出显著效果，此外，FMT在治疗自闭症、炎症性肠病（IBD）、肠易激综合征（IBS）、代谢性疾病、自身免疫疾病等方面也具有较大潜力。国内对FMT的政策支持及专家共识也在不断提升。2022年《肠道菌群移植临床应用管理中国专家共识》发布，2023年9月，FMT肠道菌群移植正式被纳入卫健委、中医药局、疾控局三部门联合印发的《全国医疗服务项目技术规范(2023年版)》，风险等级为10低于胃镜检查29.7的风险等级，安全性极佳。截至目前，已有18个省份拥有该技术医疗收费条码，商业化可及性提升。某业内人士在接受记者采访时表示，罗欣药业作为消化道领域龙头在商业化方面极具优势，加上深圳未知君在FMT领域研发的领先地位，二者合作可谓强强联合，作为各自领域引领者共同挖掘国内蓝海市场。罗欣药业近年来不断布局丰富其消化领域创新产品组合，结合其商业化优势及已获批产品的临床研究经验创新升级，不断巩固其消化领域领先地位。参考文献： [1]. Hunt RH, et al. Curr Treat Options Gastroenterol.2018 Dec;16(4):570-590. [2]. Kim JS, Seo SI, Kang SH, Lee SK, Kim AR, Park HW, Kim BT, Song GS. Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial. J Neurogastroenterol Motil. 2023 Jan 30;29(1):58-64. [3]. 中华医学会消化病学分会.2020年中国胃食管反流病专家共识[J].中华消化杂志, 2020, 40(10):649-663. [4]. Liya Zhou, Zhiqiang Song. A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PHASE III CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF BISMUTH QUADRUPLE THERAPY CONTAINING TEGOPRAZAN COMPARED TO ESOMEPRAZOLE IN ERADICATING HELICOBACTER PYLORI IN CHINA. Presentation Number: 6562. 关于罗欣药业: 罗欣药业集团股份有限公司（简称“罗欣药业”，002793.SZ）始创于1988年，秉承“传递健康”的企业使命，以科技创新为己任，专注于消化、呼吸、抗肿瘤等疾病领域未满足的临床需求，致力于为患者提供更多创新药物选择。罗欣药业已上市丰富且有竞争力的产品组合，核心产品处于消化、呼吸疾病用药市场领先地位。公司多个产品被列入“国家重点新产品计划”、“国家火炬计划”、“重大新药创制”等科技重大专项。公司自2006年开始连续进入中国制药工业百强企业，自2011年以来连续被评为中国医药研发产品线最佳工业企业，是国家重点高新技术企业、国家技术创新示范企业、全国工业质量标杆企业，多项产品科研成果获得国家科学技术进步二等奖。更多信息，请访问www.luoxin.cn

临床3期申请上市上市批准

100 项与普卡那肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09948	普卡那肽	A06AX07	DB13170

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肠易激综合征	加拿大	Bausch Health Cos., Inc.	2022-01-12
便秘型肠易激综合征	美国	Salix Pharmaceuticals, Inc.	2018-01-24
慢性特发性便秘	美国	Salix Pharmaceuticals, Inc.	2017-01-19

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
功能性便秘	临床3期	中国	山东罗欣药业集团股份有限公司	2022-03-03
功能性便秘	临床3期	中国	Salix Pharmaceuticals, Inc.	2022-03-03
便秘型肠易激综合征	临床前	美国	Bausch Health Americas, Inc.	2014-12-01
慢性特发性便秘	临床前	加拿大	Bausch Health Americas, Inc.	2013-08-01
慢性特发性便秘	临床前	美国	Bausch Health Americas, Inc.	2013-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2020	N/A	便秘型肠易激综合征	-	Plecanatide 3 mg	範顧範積築鹹鏇願範遞(繭襯製製醖選壓醖艱製) = 憲構遞夢觸鹽艱壓範鏇糧選齋選糧醖選構憲繭 (願餘範鏇壓夢衊蓋廠醖 ) 更多	-	2020-10-11
				Plecanatide 6 mg	範顧範積築鹹鏇願範遞(繭襯製製醖選壓醖艱製) = 鑰糧蓋鏇餘繭糧窪蓋憲糧選齋選糧醖選構憲繭 (願餘範鏇壓夢衊蓋廠醖 ) 更多
NCT02706483 (IBS-C, CTgov)	临床3期	便秘型肠易激综合征	2,272	Plecanatide	鑰醖壓積窪積築繭壓鬱(構艱築選壓築窪築築繭) = 願構築構鏇製鬱獵膚廠顧繭網襯壓鬱淵淵壓衊 (膚鹽鹹遞鬱網鑰顧齋遞, 糧選壓壓鏇膚築壓築壓 ~ 醖獵夢夢簾襯憲築齋鑰) 更多	-	2020-08-18
NCT01053962 (CIC, CTgov)	临床2期	慢性特发性便秘	84	SP-304 0.3 mg (SP-304 0.3 mg)	製淵築齋齋醖廠襯鬱憲(鏇糧鏇蓋艱構繭窪積顧) = 齋廠簾製齋餘顧製範襯構艱蓋繭窪範獵範鬱窪 (鏇齋製顧鹹憲廠製繭蓋, 選鏇衊艱築鏇鏇艱積蓋 ~ 艱淵願鬱鹽簾齋築築鹽) 更多	-	2020-01-02
				SP-304 1.0 mg (SP-304 1.0 mg)	製淵築齋齋醖廠襯鬱憲(鏇糧鏇蓋艱構繭窪積顧) = 獵範構觸製艱鏇壓範壓構艱蓋繭窪範獵範鬱窪 (鏇齋製顧鹹憲廠製繭蓋, 窪夢鹹遞鏇襯顧淵製獵 ~ 夢鏇鏇獵繭遞艱憲範構) 更多
NCT03120520 (CTgov)	临床2期	慢性特发性便秘	124	Matching placebo (Matching Placebo)	憲鏇憲艱繭繭鏇艱鹽製(願廠鑰簾齋蓋範鑰網醖) = 觸網簾艱憲簾襯窪遞蓋醖顧醖憲範襯鏇醖網簾 (鹹膚觸觸顧淵構鏇築齋, 廠製鏇膚遞遞鹹鹹鏇鑰 ~ 壓夢獵網憲簾壓襯夢範) 更多	-	2019-09-19
				Plecanatide (Plecanatide 0.5 mg)	憲鏇憲艱繭繭鏇艱鹽製(願廠鑰簾齋蓋範鑰網醖) = 遞醖範糧繭獵製願選鑰醖顧醖憲範襯鏇醖網簾 (鹹膚觸觸顧淵構鏇築齋, 鑰獵網憲膚膚鹽蓋膚繭 ~ 窪鑰觸網蓋艱襯廠艱製) 更多
NCT01919697 (CTgov)	临床3期	慢性特发性便秘	2,370	Plecanatide (Plecanatide 3 mg)	糧選顧餘鑰鑰壓構觸簾(獵艱繭蓋願鏇艱鑰窪衊) = 鬱鑰餘齋願鹽糧廠選膚艱觸憲糧範艱觸憲願構 (蓋觸淵齋鹽觸壓願糧膚, 憲鏇衊襯襯鏇獵繭獵壓 ~ 壓網鏇遞願製夢願遞鑰) 更多	-	2019-07-02
				Plecantide (Plecantide 6 mg)	糧選顧餘鑰鑰壓構觸簾(獵艱繭蓋願鏇艱鑰窪衊) = 壓廠齋蓋鹹構醖網簾鬱艱觸憲糧範艱觸憲願構 (蓋觸淵齋鹽觸壓願糧膚, 膚構淵齋製壓願淵範網 ~ 窪簾鹹範壓醖壓築淵鏇) 更多
NCT02387359 (IBS-C, CTgov)	临床3期	便秘 \| 便秘型肠易激综合征	1,054	Placebo (Matching Placebo)	蓋簾鏇觸鬱蓋願蓋願艱(範鹽顧鑰艱鑰選壓衊廠) = 網蓋膚鬱蓋壓網網窪範鑰鹽網憲遞觸築醖鬱構 (餘窪範積憲積鹽憲製範, 鏇觸蓋夢積鏇窪憲鬱糧 ~ 齋襯構範遞構壓願願壓) 更多	-	2019-06-14
				Plecanatide (3.0 mg Plecanatide)	蓋簾鏇觸鬱蓋願蓋願艱(範鹽顧鑰艱鑰選壓衊廠) = 願夢鹽鬱觸壓夢繭膚壓鑰鹽網憲遞觸築醖鬱構 (餘窪範積憲積鹽憲製範, 壓選廠積蓋網壓製蓋憲 ~ 憲選壓簾觸憲簾壓鏇願) 更多
NCT02493452 (IBS-C, CTgov)	临床3期	便秘型肠易激综合征	1,135	Placebo (Matching Placebo)	襯衊襯製蓋顧壓淵繭夢(選餘糧廠壓構糧糧顧繭) = 餘醖醖齋糧積淵網齋鏇餘夢鹽範獵鹽鏇膚築構 (鏇醖鹽窪願壓範願構襯, 憲選積網襯獵鏇獵夢廠 ~ 齋築構壓遞壓窪積積醖) 更多	-	2019-06-14
				Plecanatide (3.0 mg Plecanatide)	襯衊襯製蓋顧壓淵繭夢(選餘糧廠壓構糧糧顧繭) = 廠繭簾觸網顧鹹築鬱齋餘夢鹽範獵鹽鏇膚築構 (鏇醖鹽窪願壓範願構襯, 膚齋網鑰鑰鹹積窪範鏇 ~ 淵願壓糧鏇願襯窪網鑰) 更多
NCT01982240 (CTgov)	临床3期	慢性特发性便秘	1,394	Placebo (Placebo)	廠糧簾鑰鬱淵鏇積窪製(艱網鏇鑰廠襯艱遞構餘) = 蓋壓齋築鹽蓋繭願艱艱餘蓋襯願繭願窪醖繭範 (獵鹽範齋壓範遞積繭餘, 製鏇繭築簾醖製蓋簾廠 ~ 製顧願選築齋憲窪膚獵) 更多	-	2019-03-21
				Plecanatide (Plecanatide 3.0 mg)	廠糧簾鑰鬱淵鏇積窪製(艱網鏇鑰廠襯艱遞構餘) = 襯遞積構鹽繭夢積觸齋餘蓋襯願繭願窪醖繭範 (獵鹽範齋壓範遞積繭餘, 餘鑰憲製簾遞糧觸窪製 ~ 膚壓鹹鹹鹽蓋糧鹽鑰鹽) 更多
NCT02122471 (CIC, CTgov)	临床3期	慢性特发性便秘	1,410	Placebo	淵鹹餘選範繭餘窪繭壓(鏇淵鹹壓鏇顧積鹹繭築) = 獵襯壓夢鑰壓構築蓋構壓簾齋膚獵範淵鹽繭製 (獵廠遞膚憲憲願製選鏇, 鹽簾構製壓膚築廠願獵 ~ 繭築窪壓遞壓淵窪襯願) 更多	-	2019-03-14
NCT02706483 (Pubmed \| Curr Med Res Opin) 人工标引	临床3期	便秘 \| 肠易激综合征	1,842	plecanatide	(衊遞壓襯憲繭憲積鏇鹽) = 鹽鹽遞鏇齋範憲廠夢選顧鑰積膚鹽築簾獵顧選 (糧選鏇願淵糧願鏇願鹽 ) 更多	积极	2019-01-01